Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer

Yiyu Zou, Gang Zong, Yi He Ling, Roman Perez-Soler

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Regional (intratracheal or aerosol) delivery of cationic liposome-DNA complexes for gene therapy of lung disease offers distinct advantages over systemic (intravenous) administration. However, optimal formulations for early lung cancer treatment have not been established. Therefore, we investigated >50 different liposome and micelle formulations for factors that may affect their transcription efficiency and tested the ideal formulations in an in vivo mouse model. Our data showed that cationic liposomes were generally more effective at transfecting genes than were micelles of the same lipid composition, thus suggesting a role for the bilayer structure in facilitating transfection. In addition, the transfection efficiency of liposome-delivered genes was highly dependent upon the lipid composition, lipid/DNA ratio, particle size of the liposome-DNA complex, and cell lines used. By optimizing these factors in vitro and in vivo, we developed a novel liposome formulation (DP3) suitable for intratracheal administration. Using G67 liposome as control, we found that DP3 was more effective than G67 in vitro and as effective as G67 at both preventing lung tumor growth and prolonging survival in our lung cancer mouse model. We observed a positive correlation between the in vitro p53 function and the in vivo antitumoral activities of liposome-p53 formulations, which had not been reported previously in studies of an intravenous liposome gene delivery system. This correlation may facilitate the development and optimization of a liposome-p53 formulation for aerosol use in lung cancer patients.

Original languageEnglish (US)
Pages (from-to)683-696
Number of pages14
JournalCancer Gene Therapy
Volume7
Issue number5
StatePublished - 2000
Externally publishedYes

Fingerprint

Liposomes
Genetic Therapy
Lung Neoplasms
Micelles
Aerosols
Lipids
Transfection
DNA
Gene Transfer Techniques
Particle Size
Intravenous Administration
Lung Diseases
Genes
Cell Line
Lung
Survival
Growth

Keywords

  • Intratracheal administration
  • Liposome-p53
  • Lung cancer

ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this

Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. / Zou, Yiyu; Zong, Gang; Ling, Yi He; Perez-Soler, Roman.

In: Cancer Gene Therapy, Vol. 7, No. 5, 2000, p. 683-696.

Research output: Contribution to journalArticle

@article{b5e5093181df4facb5b7c998d46062b3,
title = "Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer",
abstract = "Regional (intratracheal or aerosol) delivery of cationic liposome-DNA complexes for gene therapy of lung disease offers distinct advantages over systemic (intravenous) administration. However, optimal formulations for early lung cancer treatment have not been established. Therefore, we investigated >50 different liposome and micelle formulations for factors that may affect their transcription efficiency and tested the ideal formulations in an in vivo mouse model. Our data showed that cationic liposomes were generally more effective at transfecting genes than were micelles of the same lipid composition, thus suggesting a role for the bilayer structure in facilitating transfection. In addition, the transfection efficiency of liposome-delivered genes was highly dependent upon the lipid composition, lipid/DNA ratio, particle size of the liposome-DNA complex, and cell lines used. By optimizing these factors in vitro and in vivo, we developed a novel liposome formulation (DP3) suitable for intratracheal administration. Using G67 liposome as control, we found that DP3 was more effective than G67 in vitro and as effective as G67 at both preventing lung tumor growth and prolonging survival in our lung cancer mouse model. We observed a positive correlation between the in vitro p53 function and the in vivo antitumoral activities of liposome-p53 formulations, which had not been reported previously in studies of an intravenous liposome gene delivery system. This correlation may facilitate the development and optimization of a liposome-p53 formulation for aerosol use in lung cancer patients.",
keywords = "Intratracheal administration, Liposome-p53, Lung cancer",
author = "Yiyu Zou and Gang Zong and Ling, {Yi He} and Roman Perez-Soler",
year = "2000",
language = "English (US)",
volume = "7",
pages = "683--696",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer

AU - Zou, Yiyu

AU - Zong, Gang

AU - Ling, Yi He

AU - Perez-Soler, Roman

PY - 2000

Y1 - 2000

N2 - Regional (intratracheal or aerosol) delivery of cationic liposome-DNA complexes for gene therapy of lung disease offers distinct advantages over systemic (intravenous) administration. However, optimal formulations for early lung cancer treatment have not been established. Therefore, we investigated >50 different liposome and micelle formulations for factors that may affect their transcription efficiency and tested the ideal formulations in an in vivo mouse model. Our data showed that cationic liposomes were generally more effective at transfecting genes than were micelles of the same lipid composition, thus suggesting a role for the bilayer structure in facilitating transfection. In addition, the transfection efficiency of liposome-delivered genes was highly dependent upon the lipid composition, lipid/DNA ratio, particle size of the liposome-DNA complex, and cell lines used. By optimizing these factors in vitro and in vivo, we developed a novel liposome formulation (DP3) suitable for intratracheal administration. Using G67 liposome as control, we found that DP3 was more effective than G67 in vitro and as effective as G67 at both preventing lung tumor growth and prolonging survival in our lung cancer mouse model. We observed a positive correlation between the in vitro p53 function and the in vivo antitumoral activities of liposome-p53 formulations, which had not been reported previously in studies of an intravenous liposome gene delivery system. This correlation may facilitate the development and optimization of a liposome-p53 formulation for aerosol use in lung cancer patients.

AB - Regional (intratracheal or aerosol) delivery of cationic liposome-DNA complexes for gene therapy of lung disease offers distinct advantages over systemic (intravenous) administration. However, optimal formulations for early lung cancer treatment have not been established. Therefore, we investigated >50 different liposome and micelle formulations for factors that may affect their transcription efficiency and tested the ideal formulations in an in vivo mouse model. Our data showed that cationic liposomes were generally more effective at transfecting genes than were micelles of the same lipid composition, thus suggesting a role for the bilayer structure in facilitating transfection. In addition, the transfection efficiency of liposome-delivered genes was highly dependent upon the lipid composition, lipid/DNA ratio, particle size of the liposome-DNA complex, and cell lines used. By optimizing these factors in vitro and in vivo, we developed a novel liposome formulation (DP3) suitable for intratracheal administration. Using G67 liposome as control, we found that DP3 was more effective than G67 in vitro and as effective as G67 at both preventing lung tumor growth and prolonging survival in our lung cancer mouse model. We observed a positive correlation between the in vitro p53 function and the in vivo antitumoral activities of liposome-p53 formulations, which had not been reported previously in studies of an intravenous liposome gene delivery system. This correlation may facilitate the development and optimization of a liposome-p53 formulation for aerosol use in lung cancer patients.

KW - Intratracheal administration

KW - Liposome-p53

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0034065318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034065318&partnerID=8YFLogxK

M3 - Article

C2 - 10830716

AN - SCOPUS:0034065318

VL - 7

SP - 683

EP - 696

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 5

ER -